Hikma Pharmaceuticals PLC
LSE:HIK
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Celanese Corp
NYSE:CE
|
Chemicals
|
| US |
|
General Mills Inc
NYSE:GIS
|
Food Products
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
Lowe's Companies Inc
NYSE:LOW
|
Retail
|
| US |
|
Lennar Corp
NYSE:LEN
|
Consumer products
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
| US |
|
Citigroup Inc
NYSE:C
|
Banking
|
| US |
|
Goodyear Tire & Rubber Co
NASDAQ:GT
|
Auto Components
|
| US |
|
Intel Corp
NASDAQ:INTC
|
Semiconductors
|
| US |
|
Starbucks Corp
NASDAQ:SBUX
|
Hotels, Restaurants & Leisure
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 722.5
2 083
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Celanese Corp
NYSE:CE
|
US |
|
|
General Mills Inc
NYSE:GIS
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
Lowe's Companies Inc
NYSE:LOW
|
US |
|
|
Lennar Corp
NYSE:LEN
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
Mueller Industries Inc
NYSE:MLI
|
US |
|
|
Citigroup Inc
NYSE:C
|
US |
|
|
Goodyear Tire & Rubber Co
NASDAQ:GT
|
US |
|
|
Intel Corp
NASDAQ:INTC
|
US |
|
|
Starbucks Corp
NASDAQ:SBUX
|
US |
This alert will be permanently deleted.
Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC
Other Non-Cash Items
Hikma Pharmaceuticals PLC
Other Non-Cash Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Non-Cash Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Other Non-Cash Items
$149m
|
CAGR 3-Years
24%
|
CAGR 5-Years
9%
|
CAGR 10-Years
11%
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Other Non-Cash Items
£1.3B
|
CAGR 3-Years
27%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
2%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Other Non-Cash Items
$938m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
3%
|
|
|
Verona Pharma PLC
NASDAQ:VRNA
|
Other Non-Cash Items
$39.7m
|
CAGR 3-Years
12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Indivior PLC
LSE:INDV
|
Other Non-Cash Items
-$11m
|
CAGR 3-Years
3%
|
CAGR 5-Years
9%
|
CAGR 10-Years
18%
|
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Other Non-Cash Items
£73.5m
|
CAGR 3-Years
2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
19%
|
|
Hikma Pharmaceuticals PLC
Glance View
Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. The firm is focused on developing, manufacturing, marketing and selling of a broad range of generic, branded and in-licensed pharmaceuticals products in solid, semi-solid, liquid and injectable final dosage forms. The firm operates through three segments, such as Injectables, Generics and Branded. The Injectables business develops and manufactures generic injectable products, which are primarily used in hospitals. The Generics business develops and manufactures oral and other non-injectable generic products. The Branded business develops and manufactures branded generics and markets and sells in-licensed patented products in Middle East/North Africa (MENA). The Company’s products are sold in the retail and hospital markets. The company also markets its products in Canada, which includes approximately 25 sterile injectable products, three in-licenced ophthalmic products and a pipeline of seven additional products.
See Also
What is Hikma Pharmaceuticals PLC's Other Non-Cash Items?
Other Non-Cash Items
149m
USD
Based on the financial report for Jun 30, 2024, Hikma Pharmaceuticals PLC's Other Non-Cash Items amounts to 149m USD.
What is Hikma Pharmaceuticals PLC's Other Non-Cash Items growth rate?
Other Non-Cash Items CAGR 10Y
11%
Over the last year, the Other Non-Cash Items growth was 23%. The average annual Other Non-Cash Items growth rates for Hikma Pharmaceuticals PLC have been 24% over the past three years , 9% over the past five years , and 11% over the past ten years .
You don't have any saved screeners yet
